Trial Profile

A clinical trial assessing intravenous formulation of OV329

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OV 329 (Primary)
Indications Epilepsy; Seizures
Focus Adverse reactions

Most Recent Events

13 Aug 2024 According to an Ovid Therapeutics media release, Company has paused the OV329 IV program for refractory status epilepticus.
16 Mar 2024 New trial record
08 Mar 2024 According to Ovid Therapeutics media release, the company is on track for an anticipated IND application or an equivalent regulatory application by late 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com